Hugo F. Fernandez, MD

Where You Are:

Hugo F. Fernandez, MD

Medical Oncology

For Consultation Requests or Referrals: (888) 663-3488


          •  Hematology

          •  University of Texas, M.D. Anderson Cancer Center - Division of Hematology
          •  University of Miami/Jackson Memorial Medical Center - Hematology/Oncology

          •  University of Miami/Jackson Memorial Medical Center

          •  University of Florida College of Medicine - Honors in Research

  • Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft-versus-Host Disease: Phase I Trial Results. Biol Blood Marrow Tr. 2015 Jun;21(6):1074-1082. Pubmedid: 25805300.

  • Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft vs. host disease. Haematologica. 2015 Apr. Pubmedid: 25840599.

  • Park SM, G?nen M, Vu L, Minuesa G, Tivnan P, Barlowe TS, Taggart J, Lu Y, Deering RP, Hacohen N, Figueroa ME, Paietta E, Fernandez HF, Tallman MS, Melnick A, Levine R, Leslie C, Lengner CJ, Kharas MG. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Clin Invest. 2015 Mar;125(3):1286-1298. Pubmedid: 25664853. Pmcid: PMC4362230.

  • Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee JW, Sun Z, Tallman MS, Patel J, G?nen M, Abdel-Wahab O, Levine RL, Estey EH. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia. 2015 Mar. Pubmedid: 25772026.

  • Watts JM, Wang XV, Litzow MR, Luger SM, Lazarus HM, Cassileth PA, Fernandez HF, Douer D, Zickl L, Paietta E, Rowe JM, Tallman MS. Younger adults with acute myeloid leukemia in remission for ? 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients. Leuk Res. 2014 Aug;38(8):901-906. Pubmedid: 24986381. Pmcid: PMC4326112.

  • Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, Lancet J, Fernandez H, List A, Anasetti C, Field T. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. Biol Blood Marrow Tr. 2014 Jun;20(6):776-780. Pubmedid: 24534108.

  • Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014 Apr;38(4):443-446. Pubmedid: 24439565.

  • Kunter G, Perkins JB, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona JL, Betts B, Nieder M, Anasetti C. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplant. 2014 Jan;49(1):11-16. Pubmedid: 23995098.

  • Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol. 2013 Nov;163(3):315-325. Pubmedid: 24033280.

  • Dinardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, Straley KS, Yen K, Patel JP, Agresta S, Abdel-Wahab O, Perl AE, Litzow MR, Rowe JM, Lazarus HM, Fernandez HF, Margolis DJ, Tallman MS, Luger SM, Carroll M. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013 Jun;121(24):4917-4924. Pubmedid: 23641016. Pmcid: PMC3682342.

  • Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II Study of CD4(+)-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting. Biol Blood Marrow Transplant. 2013 May;19(7):1087-1093. Pubmedid: 23632090.

  • Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013 Mar;48(3):346-350. Pubmedid: 22863723.

  • Janssen WE, Rahn D, Hackett M, Coyle D, Tomblyn M, Smilee RC, Anasetti C, Fernandez HF. Apheresis and transplant of hematopoietic progenitor cells (HPC) from allogeneic donors of age above 60 years. Bone Marrow Transplant. 2012 Dec;47(12):1520-1525. Pubmedid: 22562079.

  • Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012 Dec;97(12):1882-1889. Pubmedid: 22689677. Pmcid: PMC3590095.

  • Akalin A, Garrett-Bakelman FE, Kormaksson M, Busuttil J, Zhang L, Khrebtukova I, Milne TA, Huang Y, Biswas D, Hess JL, Allis CD, Roeder RG, Valk PJ, L?wenberg B, Delwel R, Fernandez HF, Paietta E, Tallman MS, Schroth GP, Mason CE, Melnick A, Figueroa ME. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet. 2012 Sep;8(6):e1002781. Pubmedid: 22737091. Pmcid: PMC3380828.

  • G?nen M, Sun Z, Figueroa ME, Patel JP, Abdel-Wahab O, Racevskis J, Ketterling RP, Fernandez H, Rowe JM, Tallman MS, Melnick A, Levine RL, Paietta E. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012 Sep;120(11):2297-2306. Pubmedid: 22855599. Pmcid: PMC3447784.

  • Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012 Aug;120(6):1290-1298. Pubmedid: 22723552. Pmcid: PMC3418722.

  • Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tran. 2012 Jul;18(7):1099-1107. Pubmedid: 22198540.

  • Perkins JB, Shapiro JF, Bookout RN, Yee GC, Anasetti C, Janssen WE, Fernandez HF. Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomes. Am J Hematol. 2012 Jul;87(7):673-677. Pubmedid: 22674468.

  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun;157(5):553-563. Pubmedid: 22449149. Pmcid: PMC4030553.

  • Patel JP, G?nen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012 Mar;366(12):1079-1089. Pubmedid: 22417203. Pmcid: PMC3545649.

  • Padron E, Fernandez H. Anthracycline dose intensification in young adults with acute myeloid leukemia. Ther Adv Hematol. 2012 Feb;3(1):17-27. Pubmedid: 23556109. Pmcid: PMC3573430.

  • Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan;118(2):418-427. Pubmedid: 21717444.

  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Ayala E, Perez L, Fernandez H, Fancher K, Tate C, Shaw LM, Milone MC, Gardiner JA, Miller S, Anasetti C. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. Bone Marrow Transplant. 2011 Nov;46(11):1418-1425. Pubmedid: 21132026.

  • Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E, Janssen W, Kharfan-Dabaja MA, Ochoa L, Perez L, Perkins J, Raychaudhuri J, Fernandez H, Anasetti C. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Tran. 2011 Oct;17(10):1505-1511. Pubmedid: 21385623.

  • Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, Perkins J, Fernandez H, Locke F, Perez L, Ochoa JL, Alsina M, Anasetti C. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica. 2011 Sep;96(9):1351-1356. Pubmedid: 21565902. Pmcid: PMC3166106.

  • Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, Perez L, Locke F, Alsina M, Ochoa JL, Perkins J, Tate C, Shapiro J, Conwell M, Bookout R, Anasetti C. ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2011 Aug;17(8):1237-1244. Pubmedid: 21215811.

  • Nishihori T, Fernandez HF, Coppola D, Ochoa-Bayona JL, Lancet JE, Komrokji RS, Kharfan-Dabaja MA. Hepatobiliary manifestations of acute myeloid leukemia. Leuk Res. 2011 Jun;35(6):e81-e83. Pubmedid: 21232795.

  • Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald G, Ketterling RP, Rowe JM, Lazarus HM, Tallman MS. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood. 2011 May;117(20):5306-5313. Pubmedid: 21415269. Pmcid: PMC3109705.

  • Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Field T, Perkins J, Ayala E, Perez L, Fernandez H. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone Marrow Transplant. 2011 May;46(5):641-649. Pubmedid: 20711242.

  • Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancetf J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Tran. 2011 Mar;17(3):384-393. Pubmedid: 20655389.

  • Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011 Mar;35(3):301-304. Pubmedid: 21109304.

  • Pidala J, Roman-Diaz J, Kim J, Nishihori T, Perkins J, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, Anasetti C, Kharfan-Dabaja MA. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. Int J Hematol. 2011 Feb;93(2):206-212. Pubmedid: 21246311.

  • Pidala J, Kim J, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez H, Anasetti C. Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. Biol Blood Marrow Tran. 2011 Feb;17(2):239-248. Pubmedid: 20637884.

  • Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol. 2011 Jan;3:36. Pubmedid: 20925957. Pmcid: PMC2958877.

  • Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, L?wenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010 Dec;18(6):553-567. Pubmedid: 21130701. Pmcid: PMC4105845.

  • Nishihori T, Perkins J, Kim J, Field T, Pidala J, Roman-Diaz J, Komrokji RS, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution. Am J Hematol. 2010 Nov;85(11):904-907. Pubmedid: 20890908.

  • Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri J, Alsina M, Greene J, Janssen W, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010 Aug;45(8):1347-1351. Pubmedid: 19966849.

  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Tran. 2010 Jul;16(7):937-947. Pubmedid: 20102746.

  • Pidala J, Kim J, Perkins J, Field T, Fernandez H, Perez L, Ayala E, Kharfan-Dabaja M, Anasetti C. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant. 2010 May;45(5):919-924. Pubmedid: 19767783.

  • Fernandez HF, Rowe JM. Induction therapy in acute myeloid leukemia: intensifying and targeting the approach. Curr Opin Hematol. 2010 Mar;17(2):79-84. Pubmedid: 20087177.

  • Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010 Feb;45(2):255-260. Pubmedid: 19543327.

  • Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb;85(2):197-199. Pubmedid: 20118399. Pmcid: PMC2813833.

  • Fernandez HF. New trends in the standard of care for initial therapy of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:56-61. Pubmedid: 21239771.

  • Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009 Sep;361(13):1249-1259. Pubmedid: 19776406.

  • Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J, Fernandez H, Perez L, Ayala E, Anasetti C. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Sep;15(9):1116-1121. Pubmedid: 19660725.

  • Escal?n MP, Stefanovic A, Venkatraman A, Pereira D, Santos ES, Goodman M, Byrnes JJ, Fernandez HF. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplant. 2009 Jul;44(2):89-96. Pubmedid: 19169287.

  • Fernandez HF, Kharfan-Dabaja MA. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities. Cancer Control. 2009 Apr;16(2):153-157. Pubmedid: 19337201.

  • Abou Mourad YR, Fernandez HF, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Biol Blood Marrow Tran. 2008 Sep;14(9):949-958. Pubmedid: 18721758.

  • Fernandez H, Escalon M, Pereira D, Lazarus H. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road. Bone Marrow Transplant. 2007 Sep;40(6):505-513. Pubmedid: 17589535.

  • Kharfan-Dabaja M, Abou Mourad Y, Fernandez H, Pasquini M, Santos E. Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. Biol Blood Marrow Transplant. 2007 Sep;13(9):997-1004. Pubmedid: 17697961.

  • Vance G, Kim H, Hicks G, Cherry A, Higgins R, Hulshizer R, Tallman M, Fernandez H, Dewald G. Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900). Leuk Res. 2007 May;31(5):605-9. Pubmedid: 16996130.

  • Chen M, Fernandez HL. Stimulation of beta-amyloid precursor protein alpha-processing by phorbol ester involves calcium and calpain activation. Biochem Bioph Res Co. 2004 Apr;316(2):332-340. Pubmedid: 15020222.

  • Santos E, Goodman M, Byrnes J, Fernandez H. Thalidomide effects in the post-transplantation setting in patients with multiple myeloma. Hematology. 2004 Feb;9(1):35-39. Pubmedid: 14965866.

  • Andersson BS, Kashyap A, Couriel D, Madden T, de Lima M, Thall PF, Fernandez H, Vaughan WP, Jones R, Wingard JR, Blume KG, Champlin RE. Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. Biol Blood Marrow Transplant. 2003 Nov;9(11):722-724. Pubmedid: 14682302.

  • Kharfan-Dabaja M, Morgensztern D, Santos E, Goodman M, Fernandez H. Acute graft-versus-host disease (aGVHD) presenting with an acquired lupus anticoagulant. Bone Marrow Transplant. 2003 Jan;31(2):129-131. Pubmedid: 12621495.

  • Bahlis N, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez H, Boise L, Lee K. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res. 2002 Dec;8(12):3658-3668. Pubmedid: 12473574.

  • Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, Blume K, NilandJ, Palmer J, Vaughan W, Fernandez H, Champlin R, Forman S, Andersson B. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mo. Biol Blood Marrow Transplant. 2002;8(9):493-500. Pubmedid: 12374454.

  • Fernandez H, Tran H, Albrecht F, Lennon S, Caldera H, Goodman M. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(9):486-492. Pubmedid: 12374453.

  • Andersson B, Kashyap A, Gian V, Wingard J, Fernandez H, Cagnoni P, JonesRB, Tarantolo S, Hu W, Blume K, Forman S, Champlin R. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002;8(3):145-154. Pubmedid: 11939604.

  • Santiago S, Misiakos E, De Faria W, Salgar S, Gandia C, Feo C, Berho M, Ruiz P, Fernandez H, Ricordi C, Miller J, Tzakis A. Sternum transplantation: a novel therapy for aplastic anemia in a rat model. Transplant Proc. 2001 Jun;33(4):2600-2602. Pubmedid: 11406258.

  • Andersson B, Gajewski J, Donato M, Giralt S, Gian V, Wingard J, TarantoloS, Fernandez H, Hu W, Blume K, Kashyap A, Forman S, Champlin R. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant. 2000 May;25:S35-S38. Pubmedid: 10933185.

  • Krishan A, Sridhar K, Mou C, Stein W, Lyubimov E, Hu Y, Fernandez H. Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin. Clin Cancer Res. 2000 Apr;6(4):1508-1517. Pubmedid: 10778983.

  • Santiago S, de Faria W, Khan T, Gandia C, Misiakos E, Ferrer L, Ruiz P, Coleman L, Fernandez H, Miller J, Ricordi C, Tzakis A. Heterotopic sternum transplant in rats: A new model of a vascularized bone marrow transplantation. Microsurgery. 1999;19(7):330-334. Pubmedid: 10586198.

  • Restrepo A, Albrecht F, Raez L, Fernandez H, Nassiri M, Byrne G J, Cassileth P. Post-liver transplantation lymphoproliferative disorders with and without infusions of donor bone marrow cells. Crit Rev Oncog. 1999;10(3):239-245. Pubmedid: 10468183.

  • Koya R, Andersen J, Fernandez H, Goodman M, Spector N, Smith R, Hanlon J, Cassileth P. Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants. Bone Marrow Transplant. 1998 May;21(9):923-926. Pubmedid: 9613785 .

  • Morrell L, Lee Y, Hurley J, Arias M, Mies C, Richman S, Fernandez H, Donofrio K, Raub WA J, Cassileth P. A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer. 1998 Feb;82(3):503-511. Pubmedid: 9452268 .

  • Schenkein D, Roitman D, Miller K, Morelli J, Stadtmauer E, Pecora A, Cassileth P, Fernandez H, Cooper B, Kutteh L, Lazarus H. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 1997 Oct;3(4):210-216. Pubmedid: 9360783 .

  • Garcia-Morales R, Esquenazi V, Carreno M, Karatzas T, Gomez C, Cirocco R, Zucker K, Fuller L, Alamo A, Temple D, Fernandez H, Ciancio G, Burke G 3rd, WebbM, Nery J, Roth D, Ricordi C, Tzakis A, Miller J. PCR-flow analysis used to detect the levels of chimerism in peripheral blood of bone-marrow infused organ allograft recipients at the time of rejection episodes. Transplant Proc. 1997 Jun;29(4):2179-2180. Pubmedid: 9193578 .

  • Garcia-Morales R, Esquenazi V, Zucker K, Gomez C, Fuller L, Carreno M, Cirocco R, Alamo A, Karatzas T, Burke GW 3rd, Ciancio G, Temple D, Fernandez H, Ricordi C, Tzakis A, Miller J. Assessment of the effects of cadaveric donor bone marrow on chimerism in kidney transplant recipients by the polymerase chain reaction-flow technique. Transplant Proc. 1997 Feb;29(1-2):1219-1221. Pubmedid: 9123282 .

  • Ricordi C, Karatzas T, Nery J, Webb M, Selvaggi G, Fernandez L, Khan F, Ruiz P, Schiff E, Olson L, Fernandez H, Bean J, Esquenazi V, Miller J, TzakisAG. High-dose donor bone marrow infusions to enhance allograft survival: the effect of timing. Transplantation. 1997 Jan;63(1):7-11. Pubmedid: 9000653 .

  • Reik R, Noto T, Fernandez H. Safety of large-volume leukapheresis for collection of peripheral blood progenitor cells. J Clin Apher. 1997;12(1):10-13. Pubmedid: 9097229 .

  • Garcia-Morales R, Esquenazi V, Zucker K, Gomez C, Fuller L, Carreno M, Cirocco R, Alamo A, Karatzas T, Burke GW 3rd, Ciancio G, Temple D, Fernandez H, Ricordi C, Tzakis A, Miller J. An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation. 1996 Oct;62(8):1149-1160. Pubmedid: 8900317 .

  • Ricordi C, Karatzas T, Selvaggi G, Neri J, Fernandez H, Ruiz M, LinetskyE, Kong S, Webb M, Bottino R, et a. Enhanced allograft acceptance by multiple infusions of donor bone marrow in humans. Transplant Proc. 1995 Dec;27(6):3381-3381. Pubmedid: 8540006 .

  • Ricordi C, Karatzas T, Selvaggi G, Nery J, Webb M, Fernandez H, Ruiz P, Kong S, Esquenazi V, Miller J, et a. Multiple bone marrow infusions to enhance acceptance of allografts from the same donor. Ann N Y Acad Sci. 1995 Dec;770:345-350. Pubmedid: 8597372 .

  • Ucar A, Fernandez H, Byrnes J, Lian E, Harrington WJ J. Thrombotic microangiopathy and retroviral infections: a 13-year experience. Am J Hematol. 1994 Apr;45(4):304-309. Pubmedid: 7909982 .

  • Diab A, Zickl L, Abdel-Wahab O, Jhanwar S, Gulam MA, Panageas KS, Patel JP, Jurcic J, Maslak P, Paietta E, Mangan JK, Carroll M, Fernandez HF, Teruya-Feldstein J, Luger SM, Douer D, Litzow MR, Lazarus HM, Rowe JM, Levine RL, Tallman MS. Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leuk Res. 2013 Jan;37(1):32-36. Pubmedid: 23102703.

Dr. Hugo Fernandez is the associate chair, clinical director and a senior member of the Department of Blood and Marrow Transplant at Moffitt Cancer Center.  He is also a professor of oncology at the University of South Florida.

Dr. Fernandez’s clinical and research interests include molecular therapies for acute myeloid and lymphoid disorders, developing new transplant conditioning regimens for myeloid leukemia and expanding transplantation for elderly patients.

Dr. Fernandez received his medical degree from the University of Florida College of Medicine.  He served a residency in internal medicine and was chief resident at the University of Miami-Jackson Memorial Medical Center, where he also completed a fellowship in hematology/oncology.  Dr. Fernandez then pursued additional training as an academic fellow in blood and marrow transplantation at the University of Texas – MD Anderson Cancer Center.

Prior to coming to Moffitt, Dr. Fernandez was an associate professor of clinical medicine and director of the bone marrow transplant program at the University of Miami School of Medicine and Sylvester Comprehensive Cancer Center.

Dr. Fernandez has been published in numerous peer-reviewed journals and is an ad hoc reviewer for various professional journals. He is a member of several medical organizations and serves as a board member, site inspector and accreditation board member for the Foundation for the Accreditation of Cell Therapy.

TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions